GENETIC TECHNOLOGIES LIMITED — Director's Dealing 2023

Jan 10, 2023

ASX Market Announcement

==> picture [95 x 61] intentionally omitted <==

Appendix 3Y – Change of Directors’ Interest Notice

Melbourne, Australia, 11 January 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, lodges the attached Appendix 3Y - Change of Director’s Interest Notice - for Mr Lindsay Wakefield.

In relation to the late lodgement of the attached Appendix 3Y, we advise:

• this Appendix 3Y was lodged late due to an administrative oversight. A recent reconciliation of the Company’s employee/director performance shares and options uncovered the oversight to lodge an updated Appendix 3Y for Mr Wakefield.

• the Company is aware of its obligations under ASX Listing Rules 3.19A and 3.19B, requiring the Company to notify the ASX within 5 business days when there is a change in the notifiable interest of a director in the securities of GTG. The Company has a letter of appointment in place with each director which sets out requirements to notify the Company of changes in interests. There is also a standing item on the agenda for each Board meeting requiring directors to confirm their holdings in the securities of GTG. The late lodgement of this Appendix 3Y is considered an isolated breach.

• the Company will review its current practices regarding the notification of the expiry of unlisted performance shares and employee/director options to ensure continued compliance with the ASX Listing Rules.

Authorised for release by the board of directors of Genetic Technologies Limited.

Tony Di Pietro CFO and Company Secretary

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com

Genetic Technologies Limited 60-66 Hanover Street www.genetype.com Fitzroy Victoria 3065 info@gtglabs.com Australia ABN 17 009 212 328 +61 3 8412 7000

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lindsay Peter Wakefield
Date of last notice	21 December2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Wakko Enterprises Pty Ltd
Date of change	11 December 2021
No. of securities held prior to change	Indirect – Wakko Investments Pty Ltd: 8,750,000 Performance Rights Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
Class	Performance Rights
Number acquired	Nil
Number disposed	3,750,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	Indirect – Wakko Investments Pty Ltd: 5,000,000 Performance Rights Indirect - Wakko Enterprises Pty Ltd: 9,418,104 Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Expiry ofPerformanceRights

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3